EOM Pharmaceutical Holdings, Inc. (IMUC)

Overview

Immunocellular Therapeutics, Ltd. exemplifies a pioneering spirit in the pharmaceutical industry, chiefly concentrating on the innovation of therapeutics and delivery technologies tailored for inflammatory conditions and ocular diseases. Established in 2020 and with its headquarters situated in Montvale, New Jersey, the company positions itself as a clinical-stage pharmaceutical entity. Through its dedicated research and development endeavors, Immunocellular Therapeutics endeavors to address some of the most challenging medical conditions with novel treatment modalities.

Products and Services

• EOM613 Solution

This lead clinical asset underlines the company’s commitment to revolutionizing the treatment landscape for individuals suffering from cancer cachexia and rheumatoid arthritis. EOM613 is characterized as a peptide nucleic-acid solution that exhibits dual action: it's both anti-inflammatory and pro-inflammatory, targeting cytokines and chemokines to modulate the body's immune response. The therapeutic potential of EOM613 lies in its precision mechanism, designed to balance the immune system's complexities and offer relief for chronic conditions.

• EOM 147

An investigational compound, EOM 147 highlights the company's venture into the realm of ocular diseases, particularly those that are chronic and debilitating. As a broad-spectrum aminosterol, EOM 147 functions through an intracellular mechanism, showcasing a novel approach to treating retinal diseases. Its development is pivotal, offering hope to patients grappling with conditions that lead to severe vision impairment or blindness. EOM 147 stands as a testament to Immunocellular Therapeutics' aspiration to extend the boundaries of current medical solutions.